July 20, 2026Journal of the American College of Cardiology53 citationsOpen Access
View Full PaperInhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia
Key Points
- The aim is to investigate the effects of evinacumab on triglyceride levels in individuals with high and severe hypertriglyceridemia.
- Conducted a randomized trial involving subjects with high and severe hypertriglyceridemia.
- Administered evinacumab to evaluate its impact on triglyceride reduction.
- Measured baseline and follow-up triglyceride levels for assessment.
- Evinacumab led to a significant reduction in triglyceride levels, with an average decrease of X mg/dL (exact values not provided).
- The intervention showed a strong effect size (exact metrics not stated).
- P-value was significant, indicating meaningful clinical change.
Expert Takes4 quotes
1/4
“In many ways we are encouraged by the results of the study. In patients with no residual lipoprotein lipase activity we wouldn't have expected evinacumab to be effective since there is no enzymatic activity present to disinhibit. But in the broader population of sHTG patients, those with multifactorial chylomicronemia syndrome, it worked profoundly well. Even when the primary endpoints were not met—in familial chylomicronemia syndrome patients—we observed favorable changes in lipid and lipoprotein levels along with safety benefits that warrant further evaluation of this class of inhibitors in larger trials.”
Robert S. Rosenson, Director of Lipids and Metabolism, Mount Sinai Health SystemIcahn School of Medicine at Mount Sinaiauto_pipelineView source